EuroBioForum 2013 2nd Annual Conference 27-28 May 2013 - Hilton Munich City, Munich, Germany http://www.eurobioforum.eu/2013 ======================================= # REGIONAL PERSPECTIVES # Genome Quebec, Canada: Personalised medicine – Reaching the patient? Marc LePage President and CEO Genome Quebec ======================================= http://www.eurobioforum.eu

1. PERSONALIZED MEDICINE:
OPPORTUNITIES IN QUÉBEC
Marc LePage, President and CEO, Génome Québec
EuroBioForum 2nd Annual Conference 2013
May 28, 2013
Munich, Germany

2. 1- Génome Québec in brief
2- Platforms
3- Personalized medicine portfolio
4- What do we offer?
5- What are we looking for?
6- Personalized medicine projects (4-minute video)
OUTLINES
May 28, 2013 2Marc LePage, President and CEO

3.  Launched in 2000
 Large-scale genomics research
 $750 million invested / 80 projects
 Health, Forestry, Agriculture, Environment, etc.
 Operates genomics platform
 750 researchers at all major universities
 90 employees
GÉNOME QUÉBEC IN BRIEF
May 28, 2013 3Marc LePage, President and CEO

4. May 28, 2013 4
McGILL UNIVERSITY AND GÉNOME QUÉBEC
INNOVATION CENTRE
 175 employees:
110 McGill (research): 15 research teams
65 Génome Québec (management of services): average
experience of GQ team > 4.5 years
 Number of users: > 800 research teams
 Annual revenues: $12 million
Marc LePage, President and CEO

5. May 28, 2013 5
TECHNOLOGIES AND APPLICATIONS
 Whole genome sequencing
 Exome sequencing (custom capture)
 RNA-Seq
 ChIP-Seq
 Epigenetics , methylation
 Transcriptomics, expression
 Genotyping (GWAS and custom)
 Validation (low throughput sequencing and genotyping)
 Bioinformatics
 Data analysis
Marc LePage, President and CEO

6. May 28, 2013 6
INNOVATION CENTRE TODAY
52%33%
15%
Geographical distributionof revenues of the
InnovationCentre for 2011-2012
Québec
Rest of Canada
International
Marc LePage, President and CEO

7. May 28, 2013 7
INTERNATIONAL DISTRIBUTION OF USERS
23 countries (2011-2012)
Mostly in Europe!
Marc LePage, President and CEO

8. May 28, 2013 8
COGS
MAJOR CANADA/EUROPAN UNION COLLABORATION
Marc LePage, President and CEO

9. May 28, 2013 9
INNOVATION CENTRE AND EUROPEAN UNION
Citation
“I am heading one of the largest genotype projects globally and
a large part of our nearly 250,000 samples have been
genotyped at the McGill University and Génome Québec
Innovation Centre. We are very impressed with the expertise
and professionalism of the personnel, their project management
approach and the capacity to deliver large-scale projects in a
timely manner with very high quality standards.”
Per Hall, MD, PhD; Medical Epidemiology and Biostatistics,
Karolinska Institute,and Head of the COGS International Consortium
Marc LePage, President and CEO

10. May 28, 2013 10
PERSONALIZED MEDICINE PORTFOLIO
Principal
Investigator
Institution Project Title
Total Budget
($)
Patrick Cossette
Centre hospitalier universitaire de
l’Université de Montréal (CHUM)
Personalized medicine in the treatment of epilepsy 10,833,759
Nada Jabado
Research Institute of the
McGill University Health Centre
Biomarkers for pediatric glioblastoma through
genomics and epigenomics
5,074,844
Claude Perreault
Hôpital Maisonneuve-Rosemont
and the Institute for Research in
Immunology and Cancer of
Université de Montréal
Personalized cancer immunotherapy 13,486,784
John D. Rioux
Montreal Heart Institute of
Université de Montréal
Inflammatory bowel diseases Genomic Medicine
Consortium (iGenoMed)
9,892,162
François Rousseau
Université Laval and
CHU de Québec
Personalized genomics for prenatal aneuploidy
screening using maternal blood (PEGASUS)
10,459,731
Guy Sauvageau
Institute for Research in
Immunology and Cancer of
Université de Montréal
Innovative chemo-genomic tools to improve clinical
outcome in acute myeloid leukemia
11,325,631
Jacques Simard
Université Laval and
CHU de Québec
Personalized risk stratification for the prevention and
early detection of breast cancer
11,382,455
Jean-Claude Tardif
Montreal Heart Institute of
Université de Montréal
Personalized medicine strategies for molecular
diagnostics and targeted therapeutics of cardiovascular
diseases
9,443,002
4 collaborations 6,666,950
Marc LePage, President and CEO

11. May 28, 2013 11
WHAT DO WE OFFER?
 International collaborations
 Access to genomics platform (sequencing, genotyping)
 CARTaGENE/Genizon: Population cohorts of Québec
« Colloque sur la médecine personnalisée: Parce que les
solutions sont dans nos gènes »
Investigators and health policy meeting that will be held
October 1, 2013, in Québec City
Marc LePage, President and CEO

12. May 28, 2013 12
WHAT DO WE WANT?
Today
 Translational strategies: successful models and approaches
 Collaborators, cohorts
Tomorrow
 Clinical genomics: lessons learned
 Genomics and prevention (healthy lifestyle habits…)
Marc LePage, President and CEO

13. May 28, 2013 13
PERSONALIZED MEDICINE PROJECTS
Marc LePage, President and CEO